First Humira biosimilar approved in Europe
Pharma Times ------- Amgen has won European approval for its first biosimilar, a version of AbbVie’s blockbuster Humira (adalimumab). The European Commission has approved Amgevita (biosimilar adalimumab) in all the available indications of its originator product, marking the first European licence for a biosimlar version of Humira. In doing Amgen said it had marketing authorization for “all available indications” for its biosimilar Humira, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis and moderate-to-severe Crohn's disease. To learn more click on the picture below to read the article.